talisomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

talisomycin: contains components A & B; glycopeptide related to bleomycin antibiotic from actinomycetes strain 6465-94; RN given refers to cpd with unknown MF [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	134129844
CHEMBL ID	3989770
MeSH ID	M0065898

Synonyms (3)

Synonym
talisomycin
nsc-279496
CHEMBL3989770

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
"The relative therapeutic and toxic effects of two new analogs were compared with bleomycin over a range of doses."	( Relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A. Gram, TE; Siddik, ZH; Sikic, BI, )	0.13
"Tallysomycin S10b (TLM S10b), a structural analog of bleomycin (BLM), was evaluated and compared with BLM for antitumor activity in several murine tumor systems and for toxic effects in mice and rats."	( Tallysomycin S10b: experimental antitumor activity and toxicity. Bradner, WT; Florczyk, AP; Hirth, RS; Huftalen, JB; Rose, WC; Schlein, A; Schurig, JE, 1984)	0.27

Pharmacokinetics

Excerpt	Reference	Relevance
" The slower elimination of talisomycin was reflected by a half-life (t1/2) of 10."	( Preliminary studies of the pharmacokinetics of talisomycin in the rhesus monkey. Hottendorf, GH; Lee, FH; Smyth, RD; Strong, JE; Van Harken, DR, 1981)	0.26

Dosage Studied

Excerpt	Relevance	Reference
" The sensitivities of asynchronous and synchronous cells to TLM and BLM were expressed as biphasic dose-response survival curves."	( Comparison of the response of synchronized HeLa cells to talisomycin and bleomycin. Crooke, ST; Mirabelli, CK, 1981)	0.26
" Both drugs caused dose-related increases in the whole-lung hydroxyproline content in mice, but the dose-response curves were not parallel."	( Tallysomycin S10b: experimental antitumor activity and toxicity. Bradner, WT; Florczyk, AP; Hirth, RS; Huftalen, JB; Rose, WC; Schlein, A; Schurig, JE, 1984)	0.27

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	35 (72.92)	18.7374
1990's	6 (12.50)	18.2507
2000's	4 (8.33)	29.6817
2010's	3 (6.25)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (3.92%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	49 (96.08%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
caffeine [no description available]	1.96	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
stallimycin [no description available]	3.06	1
netropsin Netropsin: A basic polypeptide isolated from Streptomyces netropsis. It is cytotoxic and its strong, specific binding to A-T areas of DNA is useful to genetics research.	3.06	1
thymidine [no description available]	2.37	2	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.	1.96	1	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	3.06	1	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
thiazoles [no description available]	2	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	1.98	1	dihydrogen
bis(1,10-phenanthroline)copper(1+) ion bis(1,10-phenanthroline)copper(1+) ion: RN given refers to (1+) ion	3.06	1
1,7-phenanthroline [no description available]	3.06	1	phenanthroline
phleomycins Phleomycins: Water-soluble, copper-containing low molecular weight polypeptides obtained from the culture medium of Streptomyces verticillus. They are specific inhibitors of DNA synthesis in bacteria and have been found to act as antitumor agents. They have also been used against rust fungi of plants.. phleomycin : A mixture of glycopeptide antibiotics originally isolated from the bacterium Streptomyces verticillus whose components all contain a thiazolinylthiazole moiety and can form complexes with redox-active metals such as Co, Cu, and Fe. (Bleomycins are very similar to phleomycins, but have a bithiazole moiety in place of the thiazolinylthiazole moiety).	4.16	5
ferric bleomycin iron bleomycin: iron-bleomycin complexes	1.98	1
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	3.06	1	actinomycin	mutagen
zinostatin Zinostatin: An enediyne that alkylates DNA and RNA like MITOMYCIN does, so it is cytotoxic.	3.46	2
bleomycetin bleomycetin: RN given refers to parent cpd	1.95	1
zorbamycin zorbamycin: antibiotic related to bleomycin & phleomycin; structure in second source. zorbamycin : A glycopeptide antibiotic found in Streptomyces flavoviridis.	3.16	1	glycopeptide	antimicrobial agent; bacterial metabolite

Condition	Relationship Strength	Studies
Metaplasia A condition in which there is a change of one adult cell type to another similar adult cell type.	1.95	1
Alveolitis, Fibrosing [description not available]	2.37	2
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	2.37	2
Experimental Neoplasms [description not available]	2.36	2
Ataxia Telangiectasia Syndrome [description not available]	1.96	1
Abnormalities, Autosome [description not available]	1.96	1
Ataxia Telangiectasia An autosomal recessive inherited disorder characterized by choreoathetosis beginning in childhood, progressive CEREBELLAR ATAXIA; TELANGIECTASIS of CONJUNCTIVA and SKIN; DYSARTHRIA; B- and T-cell immunodeficiency, and RADIOSENSITIVITY to IONIZING RADIATION. Affected individuals are prone to recurrent sinobronchopulmonary infections, lymphoreticular neoplasms, and other malignancies. Serum ALPHA-FETOPROTEINS are usually elevated. (Menkes, Textbook of Child Neurology, 5th ed, p688) The gene for this disorder (ATM) encodes a cell cycle checkpoint protein kinase and has been mapped to chromosome 11 (11q22-q23).	1.96	1
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	1.96	1
Disease, Pulmonary [description not available]	2.37	2
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1.96	1
Lung Diseases Pathological processes involving any part of the LUNG.	2.37	2
Experimental Hepatoma [description not available]	1.95	1
Adenocarcinoma, Basal Cell [description not available]	1.97	1
Colorectal Cancer [description not available]	1.97	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.97	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	1.97	1
Breathlessness [description not available]	1.97	1
Benign Neoplasms [description not available]	2.38	2
Dyspnea Difficult or labored breathing.	1.97	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.38	2
Carcinoma, Epidermoid [description not available]	1.97	1
Cancer of Head [description not available]	1.97	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	1.97	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	1.97	1
Germinoblastoma [description not available]	1.97	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	1.97	1
Aneuploid [description not available]	1.96	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.97	1
Cancer of Lung [description not available]	1.97	1
Cancer of Rectum [description not available]	1.97	1
Mucositis, Oral [description not available]	1.97	1
Incontinentia Pigmenti Achromians [description not available]	1.97	1
Lung Neoplasms Tumors or cancer of the LUNG.	1.97	1
Rectal Neoplasms Tumors or cancer of the RECTUM.	1.97	1
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	1.97	1

chemdatabank.com